# **Supporting Information**

### Szendroedi et al. 10.1073/pnas.1409229111



**Fig. S1.** Whole-body glucose disposal in lean healthy young humans after 4 h glycerol (GLY) or lipid (LIP) infusion (n = 23), glucose oxidation (striped), and lipid oxidation (plane). M value was reduced during lipid infusion ( $P < 10.10^{-7}$ ). Data are given as means ± SEM.



#### Glycerol

**Fig. 52.** (*A*) Myocellular diacylglycerol (DAG) concentrations in the membrane and cytosolic fraction and ceramide concentrations during glycerol infusion in young lean healthy controls (CON) (n = 10). Myocellular ceramides did not change during lipid infusion. (*B*) Activation of myocellular PKC $\theta$ , PKC $\delta$ , and PKC $\varepsilon$  during glycerol infusion in young lean healthy controls (n = 10-14). Data are given as means  $\pm$  SEM.



Fig. S3. Membrane (A) and cytosolic (B) fractions of myocellular DAG species concentrations in young lean healthy humans (CON) (n = 10) at baseline (white columns) and after 2.5 h (light gray columns) and after 4 h (dark gray columns) of glycerol infusion.



**Fig. S4.** (*A* and *B*) Ceramide species in young lean healthy humans (CON) (n = 7) at baseline (white columns) and after 2.5 h (middle gray columns) and after 4 h (dark gray columns) of lipid (*A*) or glycerol (*B*) infusion. (*C*) Ceramide species concentrations in CON (white columns; n = 7), in young obese humans (OBE) (light gray columns; n = 10), and in elderly obese patients with type 2 diabetes (T2D) (black columns; n = 10). Data are given as means ± SEM.



**Fig. S5.** Whole-body glucose disposal in lean healthy young humans (CON) (n = 36), in young obese humans (OB) (gray columns; n = 10), and in elderly obese patients with T2D (black columns; n = 10) (glucose oxidation, striped; lipid oxidation, plane). Compared with healthy humans, glucose disposal was reduced by 78% in OB (P < 0.005) and by 88% in T2D (P < 0.001). Data are given as means  $\pm$  SEM.



Fig. S6. Study protocol for short-term insulin resistance.

AS PNAS

#### Study protocol Chronic insulin resistance



Fig. S7. Study protocol for common insulin resistance.

PNAS PNAS

Table S1. Myocellular	DAG s	oecies i	n short	t-term a	nd con	nmon ir	isulin r	esistan	ce												
Study arous and	CI	8:1, C16	02	Q	0:4, C20	'n	C16:	:0, C20:	4	C18:	0, C20:	4	C18:	0, C18:	。	C18:	2, C18:	。	C18:	:1, C18:	0
condition	Basal	2.5 h	4 h	Basal	2.5 h	4 h	Basal	2.5 h	4 h	Basal	2.5 h	4 h I	Basal	2.5 h	4 h I	3asal	2.5 h	4 h I	Basal	2.5 h	4 h
CON																					
Glycerol																					
Cytosol, nmol/g																					
Mean	2.67	3.21	3.71	1.04	0.85	1.06	0.31	0.29	0.41	0.35	0.31	0.43	3.76	3.73	5.81	0.77	0.81	1.04	2.98	3.00	4.41
S	0.99	0.74	3.04	0.33	0.19	0.55	0.17	0.05	0.36	0.17	0.05	0.34	2.72	1.28	6.59	0.37	0.17	0.85	2.13	0.86	4.38
Membrane, nmol/g																					
Mean	11.64	12.82	15.56	11.49	8.77	13.98	0.48	0.46	0.69	1.73	1.45	2.24	3.78	4.24	6.11	2.62	2.72	3.42	4.38	4.74	6.32
SD	3.18	4.30	4.28	5.34	1.78	2.42	0.20	0.11	0.31	0.64	0.19	0.23	1.83	0.93	3.09	0.58	0.62	0.81	1.70	1.26	2.19
Lipid																					
Cytosol, nmol/g																					
Mean	3.15	8.24	3.96	1.44	1.59	1.64	0.07	0.11	0.11	0.12	0.14	0.12	5.17	5.92	4.24	0.37	0.74	0.45	1.32	3.47	1.48
SD	1.27	5.59	1.90	0.74	1.12	1.14	0.04	0.04	0.06	0.06	0.06	0.04	4.29	5.18	2.17	0.18	0.27	0.32	1.39	3.78	1.16
Membrane, nmol/g																					
Mean	14.48	27.64	19.70	15.74	20.07	17.78	0.18	0.35	0.29	0.78	1.16	0.94	5.55	6.98	6.66	1.75	3.34	2.60	3.48	6.37	4.91
S	6.46	18.19	17.63	7.48	12.86	7.65	0.08	0.11	0.17	0.38	0.31	0.49	1.83	3.37	2.02	0.78	1.05	1.27	1.41	2.68	3.77
OBE																					
Cytosol, nmol/g																					
Mean	7.21			1.15			0.12			0.21			8.18			0.70			5.76		
SD	1.38			0.44			0.04			0.05			5.61			0.28			3.76		
Membrane, nmol/g																					
Mean	15.66			9.01			0.24			1.12			8.86			2.12			6.85		
S	3.51			3.84			0.07			0.41			4.57			0.80			2.71		
T2D																					
Cytosol, nmol/g																					
Mean	9.35			1.51			0.15			0.29			11.41			1.04			7.40		
SD	7.13			0.67			0.07			0.16		•	14.01			0.65			6.06		
Membrane, nmol/g																					
Mean	20.68			11.78			0.30			1.67			10.41			3.28			9.65		
SD	8.15			5.15			0.10			0.90			7.98			1.56			6.84		

insulin
common
and
short-term
₽.
species
DAG
Myocellular
÷

DNAS Nd

DNAS

Table S2. Myocellular	DAG sp	ecies in	short-t	erm and	d comm	on insu	lin resis	tance										
	C	6:0, C16:	0:	C18	3:0, C16:	0	C18	8:1, C18:	1	C	8:1, C18:	2	C18	8:2, C18:	2	C1	6:0, C18:	2
	Basal	2.5 h	4 h	Basal	2.5 h	4 h	Basal	2.5 h	4 h	Basal	2.5 h	4 h	Basal	2.5 h	4 h	Basal	2.5 h	4 h
CON																		
Glycerol																		
Cytosol, nmol/g																		
Mean	2.01	2.04	2.55	3.18	3.37	4.32	4.71	5.13	5.86	3.39	3.73	4.13	1.61	1.73	1.97	3.55	3.54	4.30
SD	1.09	0.48	2.03	1.91	0.80	3.86	1.53	0.85	3.63	1.09	0.64	2.48	0.67	0.48	1.67	1.27	0.52	2.91
Membrane, nmol/g																		
Mean	4.47	4.68	7.37	4.94	5.32	7.59	25.63	25.03	30.43	15.76	15.95	18.54	9.03	9.20	10.29	14.49	14.41	18.11
SD	1.34	1.13	2.87	2.00	1.15	2.57	6.30	7.23	9.76	3.66	5.57	6.83	2.26	2.09	2.05	3.09	3.42	4.30
Lipid																		
Cytosol, nmol/g																		
Mean	2.15	3.42	2.36	3.51	4.87	2.93	6.64	16.30	8.79	3.00	6.45	4.26	1.18	3.03	3.15	1.92	3.99	2.91
SD	0.70	1.99	0.66	2.43	5.03	1.29	3.55	12.95	6.21	1.26	2.66	2.23	0.53	0.51	1.81	0.75	1.77	0.91
Membrane, nmol/g																		
Mean	5.39	7.91	6.60	4.75	6.24	6.10	36.15	79.51	48.21	16.69	32.24	22.40	4.80	13.02	10.33	9.64	19.66	13.72
SD	1.78	4.02	3.77	1.32	2.35	2.65	21.37	61.92	42.50	9.62	13.91	13.40	2.84	4.33	5.32	4.35	6.60	6.96
OBE																		
Cytosol, nmol/g																		
Mean	3.11			6.66			9.97			7.08			3.33			4.86		
SD	0.97			3.88			4.85			4.50			1.97			1.84		
Membrane, nmol/g																		
Mean	6.04			7.93			28.45			17.32			10.13			16.38		
SD	1.01			2.57			11.20			7.78			5.34			5.64		
T2D																		
Cytosol, nmol/g																		
Mean	4.14			8.45			11.28			8.51			3.51			5.44		
SD	2.94			6.63			8.15			5.35			2.56			2.91		
Membrane, nmol/g																		
Mean	7.40			9.77			42.18			26.67			11.90			21.56		
SD	3.63			6.54			17.14			11.25			4.82			5.25		

	Cytosoli	c fraction	Membra	ne fraction
DAG species	r	Р	r	Р
C16:0, C20:4	0.521	<0.005	0.447	<0.05
C18:0, C20:4	0.461	<0.01	0.362	<0.05
C18:2, C18:0	0.581	<0.005	0.428	<0.05
C18:1, C18:2	0.552	<0.005	0.417	<0.05
C18:2, C18:2	0.591	<0.005	0.532	<0.005
C16:0, C18:2	0.570	<0.005	0.529	<0.005

## Table S3. Myocellular DAG species correlate with $\mathsf{PKC}\theta$ activation

Pearson correlation coefficients (r) between myocellular DAG species and PKC $\theta$  activation across lean healthy humans (n = 11), young insulin-resistant obese humans (n = 10) and elderly obese humans with T2D (n = 10).

#### Table S4. Anthropometric data of study participants

	CON	OBE	T2D
n (male/female)	36 (24/12)	10 (5/5)	10 (5/5)
Age, y	28 ± 1	29 ± 2	59 ± 3*
Body mass index, kg/m <sup>2</sup>	$22.4 \pm 0.4^{+}$	41.4 ± 1.9	35.6 ± 1.2
Fasting glucose, mg/dL	86 ± 3	77 ± 3	131 ± 17*
Fasting free FA, mmol/L	0.52 ± 0.13	0.50 ± 0.18	0.76 ± 0.15
Fasting triglycerides, mg/dL	106 ± 13	137 ± 24	188 ± 20*
Hemoglobin A <sub>1c</sub> , mmol/mol	33 ± 0	34 ± 1	54 ± 5*

Data are given as means  $\pm$  SEM. FA, fatty acids.

\*P < 0.05 vs. lean healthy controls (CON) and insulin resistant OBE.

 $^{\dagger}P < 0.05$  vs. insulin resistant obese and patients with T2D.

PNAS PNAS